

## S708A Cleansing Notice

**Sydney:** AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) has today issued 1,000,000 fully paid ordinary shares (**Shares**) pursuant to the exercise of vested Performance Rights and 1,000,000 Shares pursuant to the May 2025 placement (tranche 2) following receipt of shareholder approval at the General Meeting held on 8 July 2025.

The Shares are part of a class of securities quoted on the Australian Securities Exchange Limited (ASX).

In respect of the Shares, the Company gives notice pursuant to Section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (the **Act**) of the following:

- a) the Company has issued the Shares without disclosure under Part 6D.2 of the Act; and
- b) as at the date of this notice, the Company has complied with:
  - i. the provisions of Chapter 2M of the Act as they apply to the Company; and
  - ii. Section 674 and 674A of the Act; and
- c) As at the date of this notice, there is no information to be disclosed which is excluded information (as defined in sections 708A(7) and 708(8) of the Act) that is required to be disclosed under section 708A(6)(e) of the Act.

- ENDS -

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Investor Enquiries:**

Andrew Grover, Executive Chair  
[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / [investor@echoiq.ai](mailto:investor@echoiq.ai)

Henry Jordan, Six Degrees Investor Relations  
[Henry.jordan@sdir.com.au](mailto:Henry.jordan@sdir.com.au) / +61 (0) 431 271 538

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology.  
The company is based in Sydney, Australia.